CD44 and cancer: Clearly, CD44 plays a key role in tumorigenicity and chemoresistance via multiple cell signaling pathways, and this is in agreement with our results showing that more than half of the clinical studies in this review indicate that CD44-positive cancer patients have poor chemotherapy treatment outcomes.